Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | EDNRB | P24530 | 1/20 | 0.30 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13094485 | 0.76 | NNMT (0.41) | MAPTNNMTLMNACYP2C19SMN1; SMN2 | |
| SCHEMBL15633785 | 0.72 | NNMT (0.38) | MAPTNNMTLMNACYP2C19SMN1; SMN2 | |
| SCHEMBL25226069 | 0.70 | NNMT (0.39) | MAPTNNMTLMNACYP2C19SMN1; SMN2 | |
| SCHEMBL353814 | 0.69 | NNMT (0.54) | MAPTNNMTLMNACYP2C19SMN1; SMN2 | |
| SCHEMBL29795195 | 0.69 | NNMT (0.54) | MAPTNNMTLMNACYP2C19SMN1; SMN2 | |
| SCHEMBL14174627 | 0.69 | MAPT (0.43) | MAPTLMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL21719316 | 0.67 | TXNRD1 (0.36) | MAPTLMNAKDM4ETXNRD1HTT | |
| SCHEMBL6920776 | 0.67 | KDM4E (0.39) | MAPTALDH1A1KDM4E | |
| SCHEMBL31292375 | 0.67 | NNMT (0.46) | MAPTNNMTLMNACYP2C19SMN1; SMN2 | |
| SCHEMBL19313399 | 0.66 | APP (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004740-B2 | Prodrugs of HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-26 | — | — | US | disclosed |
| US-9718819-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170173015-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173015-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | TYMP, RNGTT, REV1 | MAPT 1582/4885NNMT 322/4885LMNA 2974/4885 |
| US-10004740-B2 | Prodrugs of HIV reverse transcriptase inhibitors | TYMP, RNGTT, REV1 | MAPT 1582/4885NNMT 322/4885LMNA 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.